1. Pfizer: Mid-November earliest it can seek coronavirus vaccine OK  CTV News
  2. Pfizer confirms possible November COVID vaccine application  BNN
  3. Coronavirus vaccine: Pfizer may ask for emergency approval in late November  Global News
  4. Pfizer: EUA vaccine application could be ready by late November  CNBC Television
  5. Blue-Chip Drugmaker Moves Higher on Vaccine Announcement  Schaeffers Research
  6. View Full coverage on Google News
Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and that's if everything goes well, the company's CEO announced Friday.Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and that's if everything goes well, the company's CEO announced Friday.

Pfizer: Mid-November earliest it can seek coronavirus vaccine OK | CTV News

Pfizer Inc. said it could seek emergency-use authorization for its COVID-19 vaccine in the U.S. by late November if the shot is shown to be effective in a large late-stage trial.

Pfizer confirms possible November COVID vaccine application - BNN Bloomberg

Pfizer (PFE) stock is on the higher after the company announced it could submit an Emergency Use Authorization application by as soon as the end of November

Blue-Chip Drugmaker Moves Higher on Vaccine Announcement

Pfizer said on Friday it may file for authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November.Pfizer said on Friday it may file for authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November.

Coronavirus vaccine: Pfizer may ask for emergency approval in late November - National | Globalnews.ca

There won’t be a coronavirus vaccine ready before Election Day, despite President Donald Trump’s repeated promises and vaccine makers’ breakneck speed.

Pfizer delivers final blow to Trump's hope for preelection vaccine - POLITICO

The race for a COVID-19 vaccine is heating up as cases rise worldwide. The chair of the U.K. Vaccine Taskforce says there's a slim chance a vaccine may be ready by Christmas. CBS News foreign correspondent Charlie D'Agata reports.The race for a COVID-19 vaccine is heating up as cases rise worldwide. The chair of the U.K. Vaccine Taskforce says there's a slim chance a vaccine may be ready by Christmas. CBS News foreign correspondent Charlie D'Agata reports.

Race to find a COVID-19 vaccine as cases rise worldwide - CBS News

Record high infection rates in the Midwest are driving the latest surge in coronavirus cases that have exceeded some daily totals reported over the summer.Record high infection rates in the Midwest are driving the latest surge in coronavirus cases that have exceeded some daily totals reported over the summer.

Outbreaks in the Midwest driving surge in COVID-19 cases

Moderna stock has rallied by almost 15% over the past month, as the company continues with its phase 3 clinical trials, with late-stage clinical data likely available in the next month or so. Moderna says that it could file for emergency use authorization from the U.S. FDA around November 25...Moderna stock has rallied by almost 15% over the past month, as the company continues with its phase 3 clinical trials, with late-stage clinical data likely available in the next month or so. Moderna says that it could file for emergency use authorization from the U.S. FDA around November 25...

What’s Happening With Moderna Stock?

Trump, Biden square off in dueling town halls, U.S. Covid-19 cases reach a third peak, date set for committee vote on Barrett nomination, and other news to start your day. Trump, Biden square off in dueling town halls, U.S. Covid-19 cases reach a third peak, date set for committee vote on Barrett nomination, and other news to start your day.

Pfizer and BioNTech Vaccine Could Be Ready By the End of November. We’re All Winners. | Barron's

News, analysis and comment from the Financial Times, the worldʼs leading global business publication

Subscribe to read | Financial Times

The CDC put out a central playbook for how to distribute the shots. But how states will address these guidelines is anything but uniform.The CDC put out a central playbook for how to distribute the shots. But how states will address these guidelines is anything but uniform.

In the US, 50 States Could Mean 50 Vaccine Rollout Strategies | WIRED

The market leader in flu vaccines is trailing in the race to find an effective coronavirus vaccine.The market leader in flu vaccines is trailing in the race to find an effective coronavirus vaccine.

Sanofi and Translate Bio Have a COVID-19 Vaccine Candidate Ready for Clinical Trials | The Motley Fool

But that makes it unlikely a vaccine will be available before the US election which President Trump has promised.But that makes it unlikely a vaccine will be available before the US election which President Trump has promised.

search

Pfizer has announced plans to submit an application to the US FDA seeking approval for its Covid-19 vaccine candidate next month.Pfizer has announced plans to submit an application to the US FDA seeking approval for its Covid-19 vaccine candidate next month.

Pfizer to seek approval for Covid-19 vaccine candidate next month

Vaccine developers must provide two months of safety data on half of the trial participants following the final dose of the vaccine.Vaccine developers must provide two months of safety data on half of the trial participants following the final dose of the vaccine.

An open letter from the frontrunner COVID-19 vaccine producer published Friday ends any expectations a vaccine might be available before Election Day.An open letter from the frontrunner COVID-19 vaccine producer published Friday ends any expectations a vaccine might be available before Election Day.

Pfizer CEO letter makes Thanksgiving earliest date for COVID-19 vaccine

The mRNA coronavirus vaccine being developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) is unlikely to become available ...The mRNA coronavirus vaccine being developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) is unlikely to become available under emergency use...

Pfizer, Inc. (NYSE:PFE), (BNTX) - Pfizer CEO: Emergency Use Application For Coronavirus Vaccine Could Come In Late November | Benzinga

Pfizer CEO Albert Bourla recently suggested the company would know whether its BioNTech-shared COVID-19 vaccine works by October. Criticism ensued. Now finding himself alone in the biopharma world with that bullish estimate, the Big Pharma chief is changing his tone.Pfizer CEO Albert Bourla recently suggested the company would know whether its BioNTech-shared COVID-19 vaccine works by October. Criticism ensued. Now finding himself alone in the biopharma world with that bullish estimate, the Big Pharma chief is changing his tone.

Pfizer CEO, facing pushback, shifts COVID-19 vaccine timeline to late November | FiercePharma

US pharmaceutical giant Pfizer says it will likely apply for emergency authorization of a coronavirus vaccine in the United States as early as late November.US pharmaceutical giant Pfizer says it will likely apply for emergency authorization of a coronavirus vaccine in the United States as early as late November.

Pfizer may seek vaccine approval in late Nov. | NHK WORLD-JAPAN News

NEW: Pfizer says it hopes to seek authorisation for its COVID-19 vaccine in mid-NovemberNEW: Pfizer says it hopes to seek authorisation for its COVID-19 vaccine in mid-November

Pfizer says it hopes to seek authorisation for its COVID-19 vaccine in mid-November | Euronews

Covid-19 vaccine trials are advancing fast – but anti-vaccine sentiment is growing tooCovid-19 vaccine trials are advancing fast – but anti-vaccine sentiment is growing too

‘Stick your vaccine up your arse’ – the Covid-19 vaccine, the science and the sceptics

US pharmaceutical giant Pfizer expects to file for emergency use authorization for its Covid-19 vaccine in late November, around two weeks after the November 3 US presidential election, it said Frida…US pharmaceutical giant Pfizer expects to file for emergency use authorization for its Covid-19 vaccine in late November, around two weeks after the November 3 US presidential election, it said Frida…

Pfizer plans to seek authorization for Covid-19 vaccine next month

A Chinese COVID-19 vaccine candidate based on the inactivated whole SARS-CoV-2 virus (BBIBP-CorV) is safe and elicits an antibody response, findings from a small early-phase randomised clinical trial ...

Preliminary results find COVID-19 vaccine candidate based on inactivated SARS-CoV-2 virus is safe

India News: As the world prepares for a vaccine against Covid-19, India has started identifying around 30 crore priority beneficiaries, including high-risk populIndia News: As the world prepares for a vaccine against Covid-19, India has started identifying around 30 crore priority beneficiaries, including high-risk popul

Covid-19: Govt identifying 30 crore who will get vaccine on priority | India News - Times of India

WASHINGTON, Oct 17 — Two American companies expect to apply for emergency approval for their Covid-19 vaccines by late November, welcome news as the US crossed eight million confirmed cases amid a third surge of its coronavirus epidemic. Pfizer said yesterday it hopes to move ahead with its...WASHINGTON, Oct 17 — Two American companies expect to apply for emergency approval for their Covid-19 vaccines by late November, welcome news as the US crossed eight million confirmed cases amid a third surge of its coronavirus epidemic. Pfizer said yesterday it hopes to move ahead with its...

US hoping for two Covid-19 vaccines by end of November | World | Malay Mail

Pharmaceutical giant says if safety data from trials, expected about 2 weeks after US elections, is positive, it will go ahead with request for 'emergency use authorization'Pharmaceutical giant says if safety data from trials, expected about 2 weeks after US elections, is positive, it will go ahead with request for 'emergency use authorization'

Pfizer to seek emergency approval for COVID vaccine next month | The Times of Israel

Health authorities in Jiaxing, East China’s Zhejiang Province, announced on Thursday that the city has been administering China’s homegrown inactivated COVID-19 vaccines among high-risk groups and would gradually offer it to ordinary citizens for urgent use.

Eastern Chinese cities to offer ordinary citizens COVID-19 vaccines - Global Times

Dozens of companies, from biotech start-ups to Big Pharma, are racing to develop a safe and effective COVID-19 vaccine, because the world needs it and for the potential pay day.

The race for a COVID-19 vaccine heats up

The drug maker’s CEO said Pfizer plans to apply for emergency use authorization by late November.The drug maker’s CEO said Pfizer plans to apply for emergency use authorization by late November.

Pfizer won't be seeking emergency approval for coronavirus vaccine before election | TheHill

The drug maker’s CEO said Pfizer plans to apply for emergency use authorization by late November.The drug maker’s CEO said Pfizer plans to apply for emergency use authorization by late November.

Pfizer won't be seeking emergency approval for coronavirus vaccine before election | TheHill

Some states, including Wisconsin, are experiencing a strain on hospitals, as Pfizer announced today that it won't likely be able to apply for emergency use for its vaccine until a few weeks after the election.Some states, including Wisconsin, are experiencing a strain on hospitals, as Pfizer announced today that it won't likely be able to apply for emergency use for its vaccine until a few weeks after the election.

US surpasses 8 million COVID-19 cases | CIDRAP

Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that the company won't have data showing that the vaccine is safe before the third week of November at the earliest.Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that the company won't have data showing that the vaccine is safe before the third week of November at the earliest.

Pfizer COVID-19 Vaccine Delayed Until At Least Late November : Coronavirus Live Updates : NPR

Clinical trials of an experimental vaccine against COVID-19 which is being developed by France's Sanofi and U.S. biotech firm Translate Bio are on track to begin before the end of the year after positive results in tests on animals. Sanofi and Translate Bio said in a statement on Thursday that theClinical trials of an experimental vaccine against COVID-19 which is being developed by France's Sanofi and U.S. biotech firm Translate Bio are on track to begin before the end of the year after positive results in tests on animals. Sanofi and Translate Bio said in a statement on Thursday that the

Sanofi reports positive animal test results for potential COVID-19 vaccine

Pharmaceutical giant Pfizer has put the kibosh on any dreams of rushing out its experimental covid-19 vaccine before the U.S. election day. The good news is that the company is optimistic that its vaccine will be ready to apply for the Food and Drug Administration’s emergency use authorization (EUA) by the end of November, raising hopes that it could see use in the U.S. before the end of 2020.Pharmaceutical giant Pfizer has put the kibosh on any dreams of rushing out its experimental covid-19 vaccine before the U.S. election day. The good news is that the company is optimistic that its vaccine will be ready to apply for the Food and Drug Administration’s emergency use authorization (EUA) by the end of November, raising hopes that it could see use in the U.S. before the end of 2020.

Pfizer Says Vaccine Could Be Ready for Review by Late November

A COVID-19 vaccine could arrive before the end of 2020, based on a timeline Pfizer's CEO laid out. In an open letter posted to Pfizer's website, CEO Albert Bourla wrote, "Assuming positive data, Pfizer will apply for emergency authorization use in the U. S. soon after the safety milestone is achieved in the third week of November. " COVID-19: Find the latest news on the outbreak in West Michigan by visiting the News Channel 3 coronavirus page.A COVID-19 vaccine could arrive before the end of 2020, based on a timeline Pfizer's CEO laid out. In an open letter posted to Pfizer's website, CEO Albert Bourla wrote, "Assuming positive data, Pfizer will apply for emergency authorization use in the U. S. soon after the safety milestone is achieved in the third week of November. " COVID-19: Find the latest news on the outbreak in West Michigan by visiting the News Channel 3 coronavirus page.

Pfizer could seek November vaccine authorization | WWMT

Pfizer could seek November vaccine authorization

The head of the UK Vaccine Taskforce says it would not mean that life would get back to normal straight away.The head of the UK Vaccine Taskforce says it would not mean that life would get back to normal straight away.

sign-in

According to the recent World Bank report, an estimated 1 billion students in developing nations may be out of school. CoronavirusA World Bank report says about 1 billion students in developing countries may be out of school due to the looming second wave of COVID-19.

1 billion students in developing nations may be out of school due to second wave of COVID-19 - World Bank | Nairametrics

The chief executive of Pfizer said on Friday that the company would not apply for emergency authorization of its coronavirus vaccine before the third week of November, ruling out President Donald Trump’s assertion that a vaccine would be ready before Election Day on Nov. 3.The chief executive of Pfizer said on Friday that the company would not apply for emergency authorization of its coronavirus vaccine before the third week of November, ruling out President Donald

Won’t seek vaccine authorization before mid-November: Pfizer | Deccan Herald

The companies are testing their vaccines against a placebo in healthy volunteers to see if the rate of COVID-19 infection among those who got the vaccineThe companies are testing their vaccines against a placebo in healthy volunteers to see if the rate of COVID-19 infection among those who got the vaccine

Where are we in the COVID-19 vaccine race?

The documents were submitted to the Center of Disease Control and Prevention for review and approval.The documents were submitted to the Center of Disease Control and Prevention for review and approval.

Iowa health officials submit plan to CDC on distributing vaccine when available

LAS VEGAS (FOX5) -- Nevada's Department of Health and Human Services, Division of Public and Behavioral Health submitted a vaccine program to the Centers for Disease Control and Prevention.LAS VEGAS (FOX5) -- Nevada's Department of Health and Human Services, Division of Public and Behavioral Health submitted a vaccine program to the Centers for Disease Control and Prevention.

Nevada submits COVID-19 vaccine program to CDC | Coronavirus | fox5vegas.com

Serum Institute of India (SII) can manufacture 700-800 million vaccine doses every year. said executive director Dr Suresh Jadhav.Serum Institute of India (SII) can manufacture 700-800 million vaccine doses every year. said executive director Dr Suresh Jadhav.

Oxford COVID-19 vaccine likely to be ready by March 2021: Serum Institute of India

Pfizer chief executive Albert Bourla confirmed Friday the company will not file for regulatory authorization until the third week of November.Pfizer chief executive Albert Bourla confirmed Friday the company will not file for regulatory authorization until the third week of November.

Pfizer says it will not have a coronavirus vaccine until late November, allaying fears of a rush for approval before Election Day - The Washington Post

Investors have been closely following every twist and turn in the global race to develop a coronavirus vaccine. Yesterday it was Pfizer’s turn in the spotlight.The American pharmaceuticals companyInvestors have been closely following every twist and turn in the global race to develop a coronavirus vaccine. Yesterday it was Pfizer’s turn in the spotlight.The American pharmaceuticals company